Bausch Health Companies Inc.（BHC）財務資料BHCBausch Health Companies Inc.

Bausch Health Companies Inc. (BHC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Bausch & Lomb / International segment, accounting for 48.9% of total sales, equivalent to $1.39B. Other significant revenue streams include Salix and International Rx. Understanding this composition is critical for investors evaluating how BHC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Bausch Health Companies Inc. maintains a gross margin of 65.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.17%, while the net margin is 9.12%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BHC converts its operational activities into shareholder value.

In the context of the broader market, BHC competes directly with industry leaders such as CRON and AVBP. With a market capitalization of $2.36B, it holds a leading position in the sector. When comparing efficiency, BHC's gross margin of 65.04% stands against CRON's 53.69% and AVBP's N/A. Such benchmarking helps identify whether Bausch Health Companies Inc. is trading at a premium or discount relative to its financial performance.

Bausch Health's recent financial performance shows a significant recovery with a net income of $258 million in Q2 2026, up from a loss of $1.43 billion in Q1 2026. The gross margin has improved to 65.04%, indicating effective cost management and operational efficiency.